Number 5: Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory ...

Biosimilar SB12 or Epysqli (eculizumab-aagh; Samsung Bioepis) is equivalent to reference eculizumab (Soliris) for treating complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria ...

Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and ...

The debate over the Biosimilar Red Tape Elimination Act raises critical concerns about FDA standards, physician trust, and ...

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel ...

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...

Josh Canavan, PharmD, head of pharmacy at RazorMetrics, and Chris O'Dell, senior vice president of market solutions at Turquoise Health, discuss how the health care system must overcome patient ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

Sophia Z. Humphreys, PharmD, MHA, BCBBS, of Sutter Health in Sacramento, California, details the regulatory decisions from 2022, what's to come in 2023, and how the US biosimilars market is expected ...